The FDA has given Sagent Pharmaceuticals the go-ahead to market Mesna, a drug used to cut the risk of haemorrhagic cystitis arising from ifosfamide chemotherapy.
The treatment, a generic version of Baxter’s Mesnex, is administered by means of an injection. It will be sold in 1 mg per 10 ml multi-dose vials, offered in single doses and packs of 10.
Spokesman Jeffrey Yordon said: “Mesna is our second addition this month to our cancer supportive care product line, allowing Sagent’s sales teams to provide customers with an expanding range of products for oncology patients.”
Mesna is the latest product to be approved as part of the company’s joint venture with Strides Arcolab.
The deal sees Sagent take primary responsibility for marketing the drug in the United States.
Copyright Press Association 2010